Pfizer is pulling its sickle cell disease (SCD) treatment voxelotor (Oxbryta) from global markets after data review showed an ...

European regulators suspended the approval of Pfizer Inc.’s sickle cell anemia drug, Oxbryta, citing a higher rate of disease ...

A recent trial shows that people with depression experienced greater symptom relief after 6 months of treatment with ...

Pfizer had big hopes for a sickle-cell disease drug, as did those suffering from the disease. Things didn't turn out as ...

U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where ...

The European Medicines Agency approved Afqlir and Opuviz to treat age-related macular degeneration while reiterating its ...

The European Commission on Friday extended the authorization of the Imvanex mpox vaccine to teenagers aged 12 to 17.

The EMA has approved Penbraya for protection against invasive meningococcal disease and an update of the composition of two ...

European Union suspends Pfizer's Oxbryta for sickle cell disease due to safety concerns, urging doctors to stop use ...

Sept 26 (Reuters) - The European Medicines Agency (EMA) recommended suspending the marketing authorization for Pfizer's ...

The EU's drug watchdog Thursday called for the suspension of approval for Pfizer's medicine to treat sickle cell disease, ...

The withdrawal comes as trial results indicate safety concerns with the drug, Oxbryta, which was first approved in the U.S.